Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Increased revenue from M&A activities and the consolidation of ZOO LABO, sales of the core product Iusury, commercialization preparation costs and research and development expenses related to the U.S. IND application for F351, expenses related to the acquisition of Cullgen, share-based compensation expenses, start-up costs for new businesses, and fluctuations in foreign exchange gains and losses.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥5,526 million (YoY +3.9%) |
| Operating profit | ¥-2,749 million |
| Ordinary income | ¥-3,187 million |
| Profit attributable to owners of the parent | ¥-2,127 million |
| Net income per share | (¥38.20) |
| Equity ratio | End of the current fiscal period 60.6 / End of previous period 60.1 |
| Total assets | ¥82,595 million |
| Net assets | ¥50,519 million |
| Cash flows from operating activities | ¥-415 million |
| Cash flows from investing activities | ¥-916 million |
| Cash flows from financing activities | ¥-139 million |
| Cash and cash equivalents at end of period | ¥19,869 million |
| Full-year earnings forecast | Net Sales ¥27,158 million (YoY +1.2%) / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Pharmaceuticals Business ¥3,973 million (YoY +1.4%), Medical Equipment Business ¥1,553 million (YoY +10.9%) |
| Segment profit | Pharmaceuticals Business ¥-2,408 million, Medical Equipment Business ¥-341 million |
| Depreciation and amortization | ¥309 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | Gyre Therapeutics, Inc. completed the acquisition of Cullgen Inc. on 4 May 2026, making it a wholly owned subsidiary. The impact on the consolidated statement of financial position and consolidated income statement is currently being calculated. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 55,767,545 |
| Treasury Shares at Period-End | 13,643 |
| Factors Behind Changes in Business Performance | Increased revenue from M&A activities and the consolidation of ZOO LABO, sales of the core product Iusury, commercialization preparation costs and research and development expenses related to the U.S. IND application for F351, expenses related to the acquisition of Cullgen, share-based compensation expenses, start-up costs for new businesses, and fluctuations in foreign exchange gains and losses. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to the contribution from M&A activities conducted in the fourth quarter of 2025, sales of Iusury, promotion of Etorel and Contiva, and the contribution from ZOO LABO's results. On the earnings side, initial preparation costs for the commercialization of F351, research and development expenses related to the U.S. IND application for F351, temporary related expenses including advisory fees associated with the acquisition of Cullgen, share-based compensation expenses, and start-up costs for new businesses increased.